Houston-based Otricath is a closed-loop catheter system that changes the rules in the delivery of treatment for liver cancer.
The Otricath system is designed to deliver a treatment agent directly and exclusively to a tumor site and to extract the agent after treatment, preventing it from migrating to other parts of the patient’s body. This design is intended to concentrate the agent where it is needed most, and to minimize the side effects common in existing chemotherapy delivery methods.
“The Otricath team is very pleased to have been invited to TMCx. The support and assistance we are receiving from the great team here will speed our development and improve our prospects for sharing this innovation more broadly with the medical community.”